The role of nuclear morphometry in prediction of prognosis for rhabdomyosarcoma in children

Histopathology. 2004 Oct;45(4):352-9. doi: 10.1111/j.1365-2559.2004.01948.x.

Abstract

Aims: To determine whether nuclear morphometry can be used in pretreatment diagnostic procedures to guide the therapy of childhood rhabdomyosarcoma (RMS).

Materials and methods: Biopsy specimens obtained from 108 patients with rhabdomyosarcoma aged between 1 and 217 months treated in 12 paediatric oncology departments in Poland were evaluated. There were 65 (60.2%) specimens of embryonal rhabdomyosarcoma (RME), 32 (29.6%) of alveolar RMS (RMA) and 11 (10.2%) cases of undifferentiated RMS (RMU). The clinical data from all analysed patients were evaluated. Nuclear morphometry was performed semiautomatically on haematoxylin-eosin-stained sections using the MultiScan v.8.08 Computer Scanning System and an Olympus BX 50 microscope with a x 40 magnification lens.

Results: In the RMA subtype cells with spindle-shape nuclei were less common (P = 0.013) and cell nuclei were generally more round in comparison with RME (P = 0.033). The clinical outcome was better if the nuclei seen in biopsies of RMS were more spindle-shaped (event-free survival 0.51 and 0.23, respectively; P = 0.04) or more cells with spindle-shaped nuclei were observed (event-free survival 0.5 and 0.28, P = 0.035). RME patients with small nuclei had a better outcome then patients with large nuclei (P = 0.014). In the RMA/RMU group, patients with small tumour cell nuclei had a worse prognosis than patients with larg tumour cell nuclei (P = 0.046).

Conclusions: Nuclear morphometry is a useful tool in the assessment of children with RMS. Additionally, certain morphometric parameters could be easily applied in a selection of patients with good prognosis.

Publication types

  • Multicenter Study

MeSH terms

  • Biomarkers, Tumor / analysis*
  • Cell Nucleus
  • Child
  • Child, Preschool
  • Female
  • Humans
  • Image Processing, Computer-Assisted
  • Infant
  • Male
  • Prognosis
  • Rhabdomyosarcoma / mortality
  • Rhabdomyosarcoma / pathology*
  • Survival Analysis

Substances

  • Biomarkers, Tumor